Brixton Biosciences is pioneering a novel pain management technology known as Neural Ice™, which aims to provide long-lasting relief from pain through a simple injectable treatment. Developed at Massachusetts General Hospital, Neural Ice™ is designed to deliver targeted desensitization of pain in specific areas, with the potential for relief lasting three months or more from a single injection. The technology leverages cryoneurolysis, a process that selectively targets peripheral nerves, as demonstrated in animal models. This innovative approach is positioned to address both acute and chronic pain, marking a significant advancement in pain management strategies.

The efficacy of Neural Ice™ is supported by extensive academic research, including a first-in-human study conducted in 2023 that evaluated its safety and effectiveness in alleviating knee pain. The treatment's ability to provide enduring pain control is expected to surpass traditional local anesthesia methods, offering a more reliable solution for patients suffering from orthopedic pain. As Brixton Biosciences continues to develop its technology, the potential applications of Neural Ice™ could expand, significantly impacting the landscape of pain management and addressing a critical unmet clinical need.

United States

Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for chronic and acute pain. Their Neural Ice™ has the potential for long-lasting pain control from one injection, intended to eradicate the pain of pain.

Brixton Biosciences

Company Details